Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Analysts at SunTrust Banks issued their Q1 2018 earnings per share estimates for shares of Bellicum Pharmaceuticals in a note issued to investors on Tuesday. SunTrust Banks analyst P. Lawson forecasts that the biopharmaceutical company will post earnings of ($0.80) per share for the quarter. SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ FY2021 earnings at $1.04 EPS.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. The business’s quarterly revenue was up 18.2% on a year-over-year basis. COPYRIGHT VIOLATION NOTICE: “SunTrust Banks Comments on Bellicum Pharmaceuticals, Inc.’s Q1 2018 Earnings (BLCM)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/10/suntrust-banks-comments-on-bellicum-pharmaceuticals-inc-s-q1-2018-earnings-blcm.html.

Several other equities research analysts also recently commented on the stock. BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 18th. Finally, Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $26.20.

Shares of Bellicum Pharmaceuticals (BLCM) traded up $0.11 during trading hours on Thursday, reaching $10.26. 37,440 shares of the company’s stock traded hands, compared to its average volume of 616,079. Bellicum Pharmaceuticals has a 1 year low of $7.41 and a 1 year high of $23.11. The company has a quick ratio of 8.34, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.

Several institutional investors have recently added to or reduced their stakes in BLCM. Bank of New York Mellon Corp boosted its holdings in shares of Bellicum Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 935 shares during the period. Swiss National Bank boosted its holdings in shares of Bellicum Pharmaceuticals by 51.2% in the first quarter. Swiss National Bank now owns 44,300 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 15,000 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 29.6% in the first quarter. Ameriprise Financial Inc. now owns 192,501 shares of the biopharmaceutical company’s stock valued at $2,375,000 after buying an additional 43,955 shares during the period. American International Group Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 0.7% in the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock valued at $1,029,000 after buying an additional 610 shares during the period. Institutional investors own 55.87% of the company’s stock.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.